U.S. markets open in 4 hours 45 minutes
  • S&P Futures

    4,242.50
    -4.00 (-0.09%)
     
  • Dow Futures

    34,213.00
    -75.00 (-0.22%)
     
  • Nasdaq Futures

    14,040.25
    +10.00 (+0.07%)
     
  • Russell 2000 Futures

    2,311.00
    -4.70 (-0.20%)
     
  • Crude Oil

    72.30
    +0.18 (+0.25%)
     
  • Gold

    1,861.50
    +5.10 (+0.27%)
     
  • Silver

    27.91
    +0.21 (+0.77%)
     
  • EUR/USD

    1.2132
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    1.4990
    0.0000 (0.00%)
     
  • Vix

    17.35
    +0.96 (+5.86%)
     
  • GBP/USD

    1.4104
    +0.0022 (+0.16%)
     
  • USD/JPY

    109.9250
    -0.1090 (-0.10%)
     
  • BTC-USD

    40,053.02
    +37.80 (+0.09%)
     
  • CMC Crypto 200

    996.05
    -14.56 (-1.44%)
     
  • FTSE 100

    7,170.80
    -1.68 (-0.02%)
     
  • Nikkei 225

    29,291.01
    -150.29 (-0.51%)
     

Do Insiders Own Lots Of Shares In 180 Life Sciences Corp. (NASDAQ:ATNF)?

  • Oops!
    Something went wrong.
    Please try again later.
·5 min read
  • Oops!
    Something went wrong.
    Please try again later.

If you want to know who really controls 180 Life Sciences Corp. (NASDAQ:ATNF), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.

180 Life Sciences is a smaller company with a market capitalization of US$188m, so it may still be flying under the radar of many institutional investors. Our analysis of the ownership of the company, below, shows that institutions own shares in the company. Let's take a closer look to see what the different types of shareholders can tell us about 180 Life Sciences.

Check out our latest analysis for 180 Life Sciences

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About 180 Life Sciences?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

We can see that 180 Life Sciences does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of 180 Life Sciences, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

180 Life Sciences is not owned by hedge funds. Because actions speak louder than words, we consider it a good sign when insiders own a significant stake in a company. In 180 Life Sciences' case, its Top Key Executive, Marc Feldmann, is the largest shareholder, holding 9.3% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 7.1% and 5.0%, of the shares outstanding, respectively.

A deeper look at our ownership data shows that the top 20 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. As far I can tell there isn't analyst coverage of the company, so it is probably flying under the radar.

Insider Ownership Of 180 Life Sciences

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our information suggests that insiders maintain a significant holding in 180 Life Sciences Corp.. Insiders have a US$45m stake in this US$188m business. I would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling.

General Public Ownership

The general public, who are mostly retail investors, collectively hold 54% of 180 Life Sciences shares. This size of ownership gives retail investors collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions.

Private Company Ownership

Our data indicates that Private Companies hold 8.9%, of the company's shares. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand 180 Life Sciences better, we need to consider many other factors. Like risks, for instance. Every company has them, and we've spotted 3 warning signs for 180 Life Sciences (of which 1 doesn't sit too well with us!) you should know about.

If you would prefer check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, backed by strong financial data.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.